Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer
American Journal of Cancer Research · 2025 · 15 (1) · 217-232
DOI: 10.62347/qtwj8918 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Cancer Research, 2025. Verfasst von Yingying Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University Chengdu, Sichuan, P. R. China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University Chengdu, Sichuan, P. R. China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University Chengdu, Sichuan, P. R. China.
Zitieren
APA
Chen, Y., Liu, S., & Yin, X. (2025). Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer. American Journal of Cancer Research, 15(1), 217-232. https://doi.org/10.62347/qtwj8918
Vancouver
Chen Y, Liu S, Yin X. Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer. American Journal of Cancer Research. 2025;15(1):217-232. doi:10.62347/qtwj8918
BibTeX
@article{Chen2025,
author = {Chen, Yingying and Liu, Shiyu and Yin, Xia},
title = {Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer},
journal = {American Journal of Cancer Research},
year = {2025},
volume = {15},
number = {1},
pages = {217--232},
doi = {10.62347/qtwj8918}
}
EUVIMED